Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (7575)	10/29/1998 1:24:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

This might take lotsa tax loss sellers out of the equation.

To: LarryS who wrote (7575)	10/29/1998 2:40:00 PM
From: aknahow	Read Replies (3) \| Respond to of 17367

Larry, anyone who is not a klutz like me can download 1998, mortality for meningococcemia, in specific cities, compared to 1997. We know which cities the trials are being done. This would be a good proxy for measuring the impact of Neuprex, if any. One would do a sort of the cities and measure year to year changes in mortality and perhaps another sort on non trial cities. I can tell someone else what I want but I don't know how to use Acrobat. Where is Betty, when we need her? I do think that any big buyer would have at least looked at this information. It might provide an insight as to probability of success of the P III trials. cdc.gov BTW, besides this I think the other reason the stock might be up is because Mirthie's neighbor moved, for understandable reasons, and after some quiet time started buying XOMA.<g>